A Randomized, Open-Label, Parallel-Group, Single-Dose Study to Characterize the Absolute Bioavailability of Reslizumab (220 mg) Following Subcutaneous Administration to Healthy Subjects

Trial Profile

A Randomized, Open-Label, Parallel-Group, Single-Dose Study to Characterize the Absolute Bioavailability of Reslizumab (220 mg) Following Subcutaneous Administration to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2014

At a glance

  • Drugs Reslizumab (Primary) ; Reslizumab (Primary)
  • Indications Asthma; Oesophagitis
  • Focus Pharmacokinetics
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 28 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jan 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 02 Dec 2013 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top